Equities

Hanshang Group Co Ltd

600774:SHH

Hanshang Group Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)8.10
  • Today's Change-0.06 / -0.74%
  • Shares traded6.44m
  • 1 Year change-19.72%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year Hanshang Group Co Ltd's net income fell -32.24% from 90.33m to 61.21m despite flat revenues. A contributing factor has been an increase in the percentage of sales devoted to the cost of goods sold from 36.69% to 38.55%.
Gross margin53.60%
Net profit margin-1.23%
Operating margin0.46%
Return on assets-0.45%
Return on equity-0.31%
Return on investment-0.75%
More ▼

Cash flow in CNYView more

In 2023, Hanshang Group Co Ltd increased its cash reserves by 12.21%, or 14.41m. The company earned 247.18m from its operations for a Cash Flow Margin of 17.79%. In addition the company used 158.50m on investing activities and also paid 74.28m in financing cash flows.
Cash flow per share--
Price/Cash flow per share--
Book value per share5.80
Tangible book value per share3.91
More ▼

Balance sheet in CNYView more

Hanshang Group Co Ltd has a Debt to Total Capital ratio of 31.63%, a higher figure than the previous year's 29.60%.
Current ratio0.4385
Quick ratio0.2688
Total debt/total equity0.5032
Total debt/total capital0.3163
More ▼

Growth rates in CNY

Year on year, both dividends per share and earnings per share excluding extraordinary items growth dropped -100.00% and -32.23%, respectively. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
Div yield(5 year avg)0.26%
Div growth rate (5 year)--
Payout ratio (TTM)--
EPS growth(5 years)19.20
EPS (TTM) vs
TTM 1 year ago
-105.01
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.